Pharming Technologies B.V. Increases Its Ownership in Abliva AB (publ) to 92.70 Percent,

Pharming Group Catalyzing Investor Confidence at March Conference

As the biopharmaceutical landscape continues to evolve, Pharming Group N.V.
has emerged as a significant player, particularly in the realm of rare diseases.
In a recent press release dated February 28, 2025, the company highlighted its plans to boost investor confidence ahead of an anticipated conference in March.
Operating primarily in the rare disease sector, Pharming is known for its innovative therapies aimed at treating debilitating conditions that affect a small percentage of the population.

Investors have been closely monitoring Pharming s performance, especially in light of recent corporate developments.
As of the release date, the company s stock was trading at $7.50, reflecting the market s cautious optimism regarding its strategic initiatives and growth potential.
The company s ongoing commitment to expanding its pipeline and securing regulatory approvals is likely to be a topic of discussion at the upcoming conference, where management will address the expectations of shareholders and industry stakeholders.

Pharming s recent acquisition of a larger stake in Abliva AB (publ) has raised eyebrows within the investment community.
By CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com CSIMarket.com increasing its ownership in Abliva to 92.70 percent, Pharming has positioned itself to further enhance its capabilities in developing treatments for rare genetic disorders.
This move indicates a strategic alignment with the company s long-term goals and showcases its dedication to solidifying its presence in this specialized market.

However, it is essential to note that Pharming s recent press release contains important legal disclaimers regarding the nature of its offer, particularly for shareholders residing outside of Sweden.
The company explicitly states that the press release should not be considered an offer in jurisdictions such as Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, or any other region where such offers may be restricted by applicable laws.
Shareholders not based in Sweden are urged to conduct their own inquiries about relevant legislation and potential tax implications before making any decisions.

For stakeholders in the United States, additional guidance can be found in the section

More 's News

Pharming Group Gears Up for Financial Milestones and Stakeholder Engagement in 2025 April 24, 2025

Pharming Group Sets Stage for Growth Investor Conferences on the Horizon, March 28, 2025

Pharming Group Achieves Key Milestones in Extraordinary General Meeting of Shareholders March 4, 2025

Pharming Group Catalyzing Investor Confidence at March Conference February 28, 2025

Pharming Group to Report 2024 Financial Results What Investors Need to Know Ahead of March 13, February 27, 2025

Pharming Group Announces Leadership Change and Phase II Trial Launch Amid International Offer Restrictions February 7, 2025

Pharming Group Appoints Fabrice Chouraqui as New CEO as it Launches Phase II Clinical Trial for Leniolisib, January 21, 2025

Pharmings Bold Step: A Cash Offer to Shareholders of Abliva AB Fuels Future Innovations in Rare Disease Therapeutics, December 15, 2024

More Merger and Acquisition News

Merger and Acquisition Rogers Scores Big: CRTC Greenlights Acquisition of NBA TV Canada, June 12, 2025

Merger and Acquisition Methanex Corporation Secures Regulatory Approvals for OCI Global Acquisition, Transaction Set to Close on June 27 June 12, 2025

Merger and Acquisition BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer, June 12, 2025

Submit

Previous News

GCL Makes Nasdaq Debut with Strategic Acquisitions: A New Era in Entertainment Begins!,

Colliers to partner with leading Australian planning and advisory firm

Exodus Movements Bid for Banxa: An Expired Dream and Its Implications for Investors,

Diamondback Energy Announces Major Acquisition of Double Eagle Subsidiaries for $3 Billion in Cash and Shares

H&E Equipment Services, Inc Receives Superior Proposal from Herc Holdings Inc

Twin Disc, Inc. Seals $16.5 Million Acquisition of Kobelt Manufacturing, Eyes Expansion in Marine and Industrial Markets

PainReform Partners with DeepSolar: A Unique Cross-Industry Opportunity in Renewable Energy Expansion,

Stryker Completes Acquisition of Inari Medical, Strengthening Position in VTE Market Amid Legal Challenges

Navigator Gas Sets Sail on Expansion: Successful Acquisition of Handysize Ethylene Carriers Signals Growth,

PDF Solutions to Acquire SecureWISE to Expand the Reach of its Semiconductor Manufacturing Data Platform